Inventor
MILLER JEFFREY C
US83 patents
⚠️ This page may combine multiple inventors who share the name “MILLER JEFFREY C”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SANGAMO BIOSCIENCES INC
25 patentsUS8034598B2Oct 11, 2011
Engineered cleavage half-domains
SANGAMO BIOSCIENCES INC183 citations99
US7972854B2Jul 5, 2011
Methods and compositions for targeted cleavage and recombination
SANGAMO BIOSCIENCES INC230 citations99
US7914796B2Mar 29, 2011
Engineered cleavage half-domains
SANGAMO BIOSCIENCES INC221 citations99
US7888121B2Feb 15, 2011
Methods and compositions for targeted cleavage and recombination
SANGAMO BIOSCIENCES INC355 citations99
US9458205B2Oct 4, 2016
Modified DNA-binding proteins and uses thereof
SANGAMO BIOSCIENCES INC87 citations98
US8841260B2Sep 23, 2014
Methods and compositions for treating Huntington's Disease
SANGAMO BIOSCIENCES INC35 citations98
US9970001B2May 15, 2018
Methods and compositions for nuclease design
SANGAMO BIOSCIENCES INC26 citations94
US9376689B2Jun 28, 2016
Engineered cleavage half-domains
SANGAMO BIOSCIENCES INC8 citations92
US9222105B2Dec 29, 2015
Methods and compositions for modification of the HPRT locus
SANGAMO BIOSCIENCES INC16 citations92
US8912138B2Dec 16, 2014
DNA-binding proteins and uses thereof
SANGAMO BIOSCIENCES INC14 citations92
US10081661B2Sep 25, 2018
Methods and compositions for genome engineering
SANGAMO BIOSCIENCES INC9 citations84
US10072062B2Sep 11, 2018
Methods and compositions for modification of a HLA locus
SANGAMO BIOSCIENCES INC11 citations84
US9982245B2May 29, 2018
Compositions for linking DNA-binding domains and cleavage domains
SANGAMO BIOSCIENCES INC6 citations84
US9771403B2Sep 26, 2017
Methods and compositions for treating hemophilia
SANGAMO BIOSCIENCES INC8 citations84
US9765361B2Sep 19, 2017
Engineered cleavage half-domains for generating nuclease-mediated genomic modifications in a cell
SANGAMO BIOSCIENCES INC5 citations84
US9522936B2Dec 20, 2016
Engineered transcription activator like effector (TALE) proteins
SANGAMO BIOSCIENCES INC9 citations84
US9499597B2Nov 22, 2016
Methods and compositions for treating Huntington's disease
SANGAMO BIOSCIENCES INC7 citations84
US9493750B2Nov 15, 2016
DNA-binding proteins and uses thereof
SANGAMO BIOSCIENCES INC4 citations84
US9322005B2Apr 26, 2016
DNA-binding proteins and uses thereof
SANGAMO BIOSCIENCES INC6 citations84
US9150879B2Oct 6, 2015
Engineered cleavage half-domains
SANGAMO BIOSCIENCES INC5 citations84
US8895264B2Nov 25, 2014
Methods and compositions for modification of the HPRT locus
SANGAMO BIOSCIENCES INC10 citations84
US8349810B2Jan 8, 2013
Methods for targeted cleavage and recombination of CCR5
SANGAMO BIOSCIENCES INC6 citations84
US9388426B2Jul 12, 2016
Methods and compositions for inactivating glutamine synthetase gene expression
SANGAMO BIOSCIENCES INC6 citations83
US10724020B2Jul 28, 2020
Compositions for linking DNA-binding domains and cleavage domains
SANGAMO BIOSCIENCES INC2 citations73
US9963715B2May 8, 2018
Methods and compositions for treatment of a genetic condition
SANGAMO BIOSCIENCES INC3 citations73
SANGAMO THERAPEUTICS INC
11 patentsUS10640790B2May 5, 2020
Artificial nucleases including engineered FokI cleavage half-domains
SANGAMO THERAPEUTICS INC3 citations84
US10563184B2Feb 18, 2020
Regulation of gene expression using engineered nucleases
SANGAMO THERAPEUTICS INC7 citations84
US10435677B2Oct 8, 2019
Genetically modified human cell with a corrected mutant sickle cell mutation
SANGAMO THERAPEUTICS INC8 citations84
US10407476B2Sep 10, 2019
Methods and compositions for treating hemophilia
SANGAMO THERAPEUTICS INC4 citations84
US10265377B2Apr 23, 2019
Methods and compositions for treating Huntington's Disease
SANGAMO THERAPEUTICS INC4 citations84
US10253333B2Apr 9, 2019
DNA-binding proteins and uses thereof
SANGAMO THERAPEUTICS INC5 citations84
US10066242B2Sep 4, 2018
Artificial nucleases comprising engineered cleavage half-domains
SANGAMO THERAPEUTICS INC5 citations84
US11661612B2May 30, 2023
DNA-binding proteins and uses thereof
SANGAMO THERAPEUTICS INC1 citations73
US11136599B2Oct 5, 2021
Artifical nucleases comprising engineered cleavage half-domains
SANGAMO THERAPEUTICS INC2 citations73
US10975393B2Apr 13, 2021
Engineered target specific nucleases
SANGAMO THERAPEUTICS INC2 citations73
US10968261B2Apr 6, 2021
Methods and compositions for genome engineering
SANGAMO THERAPEUTICS INC2 citations73
DOYON YANNICK
2 patentsGREGORY PHILIP D
2 patentsMILLER JEFFREY C
2 patentsDOW AGROSCIENCES LLC
2 patentsUS9914930B2Mar 13, 2018
FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
DOW AGROSCIENCES LLC6 citations82
US9493779B2Nov 15, 2016
FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
DOW AGROSCIENCES LLC8 citations81
COLLINGWOOD TREVOR
1 patentDEKELVER RUSSELL
1 patentHOLMES MICHAEL C
1 patentURNOV FYODOR
1 patentLIU PEI-QI
1 patentCAI QIHUA
1 patentShowing the top 50 of 83 patents by PatentIndex Score.